Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Director's Dealing 2012

Feb 21, 2012

5262_ffr_2012-02-21_9859b59b-3355-400a-bbbc-a7bdc315d440.zip

Director's Dealing

Open in viewer

Opens in your device viewer

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending February 2012

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors and Persons Discharging Managerial Responsibility

I give below details of changes in the interests of Persons Discharging Managerial Responsibility (PDMRs), in the Ordinary shares of GlaxoSmithKline plc as a result of the sale of Ordinary shares at a price of £14.15 per share on 17 February 2012, to meet their tax liabilities following the vesting of awards granted in 2009 under the GlaxoSmithKline Share Value Plan:

Name of PDMR Number of shares sold Number of shares retained
Mr P Thomson 900 830
Mrs V Whyte 900 830

The Company and PDMRs were advised of these transactions on 21 February 2012.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

21 February 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: February 21, 2012

By: VICTORIA WHYTE


Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc